CN101606908B - Decoquinate soluble powder and preparation method thereof - Google Patents
Decoquinate soluble powder and preparation method thereof Download PDFInfo
- Publication number
- CN101606908B CN101606908B CN2009100410221A CN200910041022A CN101606908B CN 101606908 B CN101606908 B CN 101606908B CN 2009100410221 A CN2009100410221 A CN 2009100410221A CN 200910041022 A CN200910041022 A CN 200910041022A CN 101606908 B CN101606908 B CN 101606908B
- Authority
- CN
- China
- Prior art keywords
- soluble powder
- preparation
- decoquinate
- deccox
- ecoquinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention provides ecoquinate soluble powder and a preparation method thereof. The preparation method comprises the steps: evenly mixing ecoquinate and a solid dispersion carrier together; heating the mixture to a fusing state at the temperature of 120DEG C to 150 DEG C; then, airing and crashing the mixture at room temperature; adding anhydrous dextrose to obtain the ecoquinate soluble powder. The decoquinate soluble powder comprises 1 percent to 20 percent of ecoquinate, 4 percent to 80 percent of solid dispersion carrier and anhydrous dextrose. The prepared soluble powder has good solubility and high stability, the property and the solubility of the soluble powder are not changed after being stored for 6 mouths under an accelerating test condition (40DEG C+/-2DEG C) or being stored for 1 year at room temperature (25DEG C+/-2DEG C ), the content of the ecoquinate soluble powder is reduced and meets the requirements of galenic pharmacy, the effective period of the ecoquinate soluble powder can be as long as 3 years by calculation, the content reduction is not obvious under an illumination experiment condition, and the content of drug active ingredients can be maintained above 90 percent for four hours in water. A prepared drug preparation has good effect and convenient use and has good popularization and application value.
Description
Technical field
The present invention relates to poultry soluble powder technique, particularly against-coccidia pharmaceutical formulation Decoquinate soluble powder and preparation method thereof.
Background technology
The coccidiosis of chicken is mainly that the intestinal protozoan parasite by Eimeria causes.Chicken coccidiosis has following characteristics: the one, and ubiquity, extensively occur.Coccidiosis all occurs in the place of nearly all poultry, and particularly in today of development scale, intensive aviculture, coccidiosis is quite outstanding on the impact of poultry.If can not effectively control coccidiosis, the sickness rate of chicken can reach 50%～70%, and mortality rate reaches 20～30%, reaches 80% when serious, and easily brings out other diseases.Coccidiosis has become the global disease of obstruction set reduction poultry production development.The 2nd, hazardness is large, and coccidiosis can be summarized as three aspects: to the harm that the chicken group causes: 1, cause large quantities of morbidities and the death of chicken; 2, hinder the chicken growth promoter, lose weight and can reach 30～70%; 3, reduce the price of deed.
For a long time, the coccidiosis of chicken is still take medical treatment as major way.Anticoccidial drug for the harm that alleviates chicken coccidiosis, improve the price of deed, the aspects such as development of guaranteeing poultry husbandry are all bringing into play effect greatly.But along with reasons such as coccidiostat are widely used, using method is improper, the chicken coccidiosis has almost all produced drug resistance to a certain degree to all used coccidiostats, cause the anticoccidial drug service life to shorten, prevent and treat failure or poor effect, as Salinomycin, sulfa drugs, Maduramicin, monensin, clopidol etc., the coccidiosis drug resistance has become the most serious problem in the treating and preventing coccidiosis of chicken countermeasure, to poultry husbandry, has caused huge economic loss.In addition,, because European Union, Japan, the U.S. etc. comprise multiple coccidiostat to not allowing to add list of substance in the import poultry product, cause the application of coccidiostat to be subject to great restriction.Therefore, seek a kind of sensitivity, efficient, safe coccidiostat, just become the emphasis of domestic each veterinary drug manufacturing enterprise research and development.
Deccox, chemistry Deccox by name, for the quinolines coccidiostat, has efficient chemism and low toxicity, it has good effect to the chicken coccidiosis that 7 kinds of coccidiosiss of Eimeria cause, is mainly used in preventing the chicken coccidiosis that is caused by various coccidiosiss.Since entering Chinese market in 2004, in China each department, all kept higher sensitivity.
Suo Xun etc. show the test of pesticide effectiveness of deccox prevention artificial challenge broiler chicken Eimeria Tenella disease, use in deccox group chicken group's feces and cecal content and egg capsule all do not detected, the anticoccidial index is all greater than 180, belong to efficient coccidiostat, Eimeria Tenella is infected to have prevent preferably curative effect.According to Guo etc., deccox all has sensitivity preferably to laboratory Eimeria Tenella sensitive strain with the 20 strain field strains that separate at chicken house.Simultaneously; deccox has excellent anticoccidial effect and growth promotion performance, and the coccidiosis life cycle namely start in early days play a role, can effectively protect intestinal to avoid the infringement of coccidiosis; and the continuous action time is long, to endangering 7 kinds of maximum chicken coccidiosiss, good effect is arranged.Deccox toxicity is low, and better tolerance is used 80 times of recommended amounts still safety, and metabolism is fast, and in each tissue, left drug concentration is low, is that the whole world is unique by the chemical type anticoccidial drug of Japan, European Union, the U.S., Chinese Government's approval use.
In sum, deccox was a kind of novel against-coccidia medicine with wide application prospect, but a kind of dosage form of pre-mixing agent is only arranged at present, and Qingdao health ground benefactor department has developed 3% deccox solution in 2008.
Deccox is water insoluble, also is insoluble to most organic solvents, and therefore how solving its dissolubility becomes a difficult problem.
Summary of the invention
The objective of the invention is in order to overcome the deficiency of anticoccidial sensitive medicaments in the market, simultaneously also in order to overcome the inferior position of deccox pre-mixing agent on result of use and ease of use, and the defect that exists of deccox solution, the poultry production of spreading unchecked for anticoccidial drug provides a kind of sensitivity, high-quality and efficient, low toxicity, Decoquinate soluble powder easy to use and preparation method thereof.
For achieving the above object, the present invention, through lot of experiments, has adopted following technical scheme:
The preparation method of Decoquinate soluble powder, the method is with deccox, solid dispersion carrier mix homogeneously, be heated to molten condition in 120 ℃～150 ℃, then at room temperature dry, pulverize and make Decoquinate soluble powder, perhaps add again anhydrous glucose to mix and make Decoquinate soluble powder.
In above-mentioned preparation method, the weight ratio of deccox and solid dispersion carrier is 1: 2～1: 8.
In above-mentioned preparation method, the percentage ratio that the consumption of deccox, solid dispersion carrier and anhydrous glucose accounts for these three kinds of material gross weights is respectively 1%～20%, and 4%～80% and 0%～85%.
In above-mentioned preparation method, described solid dispersion carrier is at least two kinds in PLURONICS F87, poloxamer188, polyethylene glycol 6000, Macrogol 4000, PVP K30.
In above-mentioned preparation method, after described pulverizing, cross 60 mesh sieves, then add anhydrous glucose mix and get final product.
In above-mentioned preparation method, described deccox with before the solid dispersion carrier mixes through pulverization process.
The present invention has carried out stability test to the Decoquinate soluble powder that above-mentioned preparation method makes, comprise accelerated test, long term test, exposure experiments to light and water stability test, result shows, this soluble powder stability is high, deposited 6 months under accelerated test condition (40 ℃ ± 2 ℃), or deposited 1 year under room temperature (25 ℃ ± 2 ℃), character, dissolubility all do not change, and content descends and meets the galenic pharmacy requirement; Content descends not obvious under the exposure experiments to light condition; Effective ingredient 4 hours content in drinking-water can keep more than 90%.
Specifically, the present invention has following advantage and beneficial effect:
The Decoquinate soluble powder that the present invention makes has following advantages with deccox pre-mixing agent, deccox solution phase ratio:
1, the medicinal property by deccox determines, its granule is thinner, and anti-ball effect is stronger, and make diameter is the good effect of microgranule competence exertion of 1.8 microns left and right.And such requirement is concerning pre-mixing agent, having relatively high expectations on preparation process, and the most of manufacturers of China all can not reach.And the medicine in solid dispersion is to be dispersed in formed dispersion in solid-state carrier with molecule, colloidal state, crystallite or amorphous state etc.; the dissolubility of medicine and dissolution rate will significantly be accelerated; anticoccidial effect strengthens than common pre-mixing agent; simultaneously simple on preparation technology, easily accomplish scale production.
2, after the chicken morbidity, in situation, feed intake can descend mostly, and the amount of drinking water impact is little., if the use pre-mixing agent, make drug level can not reach effective dose because the foodstuff amount is few, easily affect the state of an illness adversely.And Decoquinate soluble powder adopts the drinking-water administration, can not affect the absorption of medicine effective dose.
Although 3 deccox solution have solved the problem of drinking-water administration, it is a much progress, but owing to having used the organic solvents such as N-Methyl pyrrolidone, dimethyl acetylamide in solution, these organic solvents can produce certain toxicity to animal body, so stipulate that general consumption must not surpass 60% of preparation total amount, and comparatively inconvenience of the transportation of solution.And the solid dispersion carrier that uses in the Decoquinate soluble powder formula is all more general, does not have toxicity problem, and the powder packing is simple, convenient transportation.
, by relatively, can find out that Decoquinate soluble powder all has incomparable advantage in result of use, ease of use, safety and convenient transportation, and many a kind of dosage form selection are provided for the drinking-water administration.
The present invention determines through a large amount of test, the particularly screening of solid dispersion carrier and preparation technology (parameter), has solved the deccox indissoluble and has dissolved rear unsettled problem.On preparation technology, adopt solid dispersion technology, effectively improved dissolubility and the dissolution rate of medicine.The soluble powder dissolubility that makes is good, stability is high, deposited 6 months under accelerated test condition (40 ℃ ± 2 ℃), or deposited 1 year under room temperature (25 ℃ ± 2 ℃), character, dissolubility all do not change, content descends and meets the galenic pharmacy requirement, through calculating its effect duration, can reach 3 years; Content descends not obvious under the exposure experiments to light condition; Effective ingredient 4 hours content in drinking-water can keep more than 90%.
The present invention adopts solid dispersion technology, the deccox of utmost point indissoluble is made soluble powder, can guarantee that this soluble powder can be dispersed in use maintenance in drinking-water and stablize, overcome the deficiency of pre-mixing agent spice inequality, greatly improved the convenience that insoluble drug uses, improved the anticoccidial effect of medicine, for plant provides a kind of sensitivity, efficient, low toxicity, stable, easy to use coccidiostat.
The specific embodiment
, below in conjunction with specific embodiment, the specific embodiment of the present invention is described in detail, but not protection scope of the present invention is limited to specific details.
Embodiment 1
Table 1
| Composition | 100g (always) |
| Deccox | 1g |
| Macrogol 4000 | 1g |
| PVP K30 | 1g |
| Anhydrous glucose | 97g |
The raw material consumption of the present embodiment is as shown in table 1.
Preparation method and step: the deccox raw material of the pulverization process of learning from else's experience, Macrogol 4000, PVP K30, mix after 30 minutes and take out in mixer; Mixed sample is heated 3 hours to molten condition with 125 ℃ in baking oven; Fused mass is taken out, dry at ambient temperature, pulverize; Add anhydrous glucose, mix 30min in mixer; Press the packing of loading amount specification, the sealing of product, obtain 1% (weight) Decoquinate soluble powder.
Embodiment 2
The raw material consumption of the present embodiment is as shown in table 2.
Preparation method and step: the deccox raw material of the pulverization process of learning from else's experience, Macrogol 4000, PVP K30, mix after 30 minutes and take out in mixer; With mixed sample in baking oven 135 ℃ the heating 3 hours to molten condition; Fused mass is taken out, dry at ambient temperature, pulverize; Add anhydrous glucose, mixed 30 minutes in mixer; Press the packing of loading amount specification, the sealing of product, obtain 3% Decoquinate soluble powder.
Table 2
| Composition | 100g (always) |
| Deccox | 3g |
| Macrogol 4000 | 6g |
| PVP K30 | 6g |
| Anhydrous glucose | 85g |
Embodiment 3
Table 3
| Composition | 100g (always) |
| Deccox | 6g |
| Polyethylene glycol 6000 | 12g |
| PLURONICS F87 | 12g |
| Anhydrous glucose | 70g |
The raw material consumption of the present embodiment is as shown in table 3.
Preparation method and step: the deccox raw material of the pulverization process of learning from else's experience, polyethylene glycol 6000, PLURONICS F87, mix after 30 minutes and take out in mixer; With mixed sample in baking oven 130 ℃ the heating 3 hours to molten condition; Fused mass is taken out, dry at ambient temperature, pulverize; Add anhydrous glucose, mixed 30 minutes in mixer; Press the packing of loading amount specification, the sealing of product, obtain 6% Decoquinate soluble powder.
Embodiment 4
The raw material consumption of the present embodiment is as shown in table 4.
Preparation method and step: the deccox raw material of the pulverization process of learning from else's experience, polyethylene glycol 6000, poloxamer188, mix after 30 minutes and take out in mixer; With mixed sample in baking oven 130 ℃ the heating 3 hours to molten condition; Fused mass is taken out, dry at ambient temperature, pulverize; Add anhydrous glucose, mixed 30 minutes in mixer; Press the packing of loading amount specification, the sealing of product, obtain 10% Decoquinate soluble powder.
Table 4
| Composition | 100g (always) |
| Deccox | 10g |
| Polyethylene glycol 6000 | 40g |
| Poloxamer188 | 40g |
| Anhydrous glucose | 10g |
Embodiment 5
The raw material consumption of the present embodiment is as shown in table 5.
Preparation method and step: the deccox raw material of the pulverization process of learning from else's experience, polyethylene glycol 6000, PLURONICS F87, mix after 30 minutes and take out in mixer; With mixed sample in baking oven 140 ℃ the heating 3 hours to molten condition; Fused mass is taken out, dry at ambient temperature, pulverize; Press the packing of loading amount specification, the sealing of product, obtain 20% Decoquinate soluble powder.
Table 5
| Composition | 100g (always) |
| Deccox | 20g |
| Polyethylene glycol 6000 | 60g |
| PLURONICS F87 | 20g |
Stability test
1, the stability test design, as shown in table 6.
Table 6
2, test material, as shown in table 7.
Table 7
3, concrete test method and step:
Accelerated test: Decoquinate soluble powder is put in 40 ℃ ± 2 ℃ calorstats, placed 6 months, sample while immediately being sampled as zero,, in sampling at the 1st, 2,3,6 the end of month, detect by stability high spot reviews project, and sample compares with zero the time.
Long-term stable experiment: Decoquinate soluble powder is put under 25 ℃ ± 2 ℃ environment, placed 1 year in the 0th, 3,6,9,12 the end of month samplings, by stability high spot reviews project, detect, and sample compares with zero time.
Exposure experiments to light: Decoquinate soluble powder is put in the clarity detecting apparatus that intensity of illumination is 4500LX, placed 20 days under room temperature,, sampling in 1,3,5,10,15,20 day, by stability high spot reviews project, detect respectively, and sample compares with zero the time.
Effective ingredient water stability test: add tap water and mineral water to be diluted to Decoquinate soluble powder and contain the approximately concentration of 45 μ g/mL of deccox, be positioned under room temperature environment in airtight container, sample while being sampled as immediately zero, and respectively at the point in time sampling of 1,2,4,8,12,24 hour, detect under each time point the concentration of deccox in the solution of drinking water, sample concentration is as 100% take zero the time, conversion percentage ratio when the relative concentration of other times point is zero, to investigate the stability of deccox in aqueous solution.
Result of the test
1, accelerated test: under 40 ± 2 ℃ of conditions of temperature, the Decoquinate soluble powder accelerated test, result is as shown in table 8.
Table 8
2, long-term stable experiment: under 25 ± 2 ℃ of conditions of temperature, it is as shown in table 9 that the Decoquinate soluble powder long term test is investigated result.
Table 9
3, exposure experiments to light: Decoquinate soluble powder exposure experiments to light result is as shown in table 10.
Table 10
4, effective ingredient is tested at water stability, and the stability test result of Decoquinate soluble powder effective ingredient in water is as shown in table 11.
Above-mentioned result of the test shows, this soluble powder stability is high, accelerated test 6 months, long term test 1 year and exposure experiments to light 20 days, and character, the dissolubility of three batches of Decoquinate soluble powders all do not change, content descends and meets the galenic pharmacy requirement, through calculating its effect duration, can reach 3 years; Content descends not obvious under the exposure experiments to light condition; Effective ingredient 4 hours content in drinking-water can keep more than 90%.
Table 11
In order to prove the stability of against-coccidia pharmaceutical formulation Decoquinate soluble powder provided by the invention, chosen a routine embodiment and carried out above-mentioned accelerated test, long-term stable experiment, exposure experiments to light and the medicament effective component stability test in water, result of the test has shown feasibility of the present invention.
Above-described embodiment; the composition, preparation technology and the stability test that comprise Decoquinate soluble powder; the present invention is described in detail; these descriptions are illustrative but not determinate; can list several embodiment according to institute's limited range; therefore in the variation and the modification that do not break away under general plotting of the present invention, within should belonging to protection scope of the present invention.
Claims (5)
1. the preparation method of Decoquinate soluble powder, it is characterized in that deccox, solid dispersion carrier mix homogeneously, be heated to molten condition in 120 ℃～150 ℃, then at room temperature dry, pulverize and make Decoquinate soluble powder, perhaps add again anhydrous glucose to mix and make Decoquinate soluble powder; Described solid dispersion carrier is at least two kinds in PLURONICS F87, poloxamer188, polyethylene glycol 6000, Macrogol 4000, PVP K30; The percentage ratio that the consumption of deccox, solid dispersion carrier and anhydrous glucose accounts for these three kinds of material gross weights is respectively 1%～20%, and 2%～80% and 0%～85%; The weight ratio of deccox and solid dispersion carrier is 1: 2～1: 8.
2. preparation method according to claim 1, the percentage ratio that the consumption that it is characterized in that deccox, solid dispersion carrier and anhydrous glucose accounts for these three kinds of material gross weights is respectively 1%～20%, 4%～80% and 0%～85%.
3. preparation method according to claim 1 and 2, after it is characterized in that described pulverizing, cross 60 mesh sieves, then add anhydrous glucose mix and get final product.
4. preparation method according to claim 3, it is characterized in that described deccox with before the solid dispersion carrier mixes through pulverization process.
5. the Decoquinate soluble powder that is made by the described method of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100410221A CN101606908B (en) | 2009-07-10 | 2009-07-10 | Decoquinate soluble powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100410221A CN101606908B (en) | 2009-07-10 | 2009-07-10 | Decoquinate soluble powder and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101606908A CN101606908A (en) | 2009-12-23 |
| CN101606908B true CN101606908B (en) | 2013-11-20 |
Family
ID=41480924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100410221A Active CN101606908B (en) | 2009-07-10 | 2009-07-10 | Decoquinate soluble powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101606908B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101933930B (en) * | 2010-08-23 | 2012-05-23 | 山东步步赢生物科技有限公司 | Novel compound anti-coccidiosis medicament and preparation method thereof |
| CN102274189A (en) * | 2011-07-21 | 2011-12-14 | 瑞普（天津）生物药业有限公司 | Decoquinate-containing suspension formula and preparation method thereof |
| JP6698161B2 (en) * | 2015-12-08 | 2020-05-27 | 広州藍亮医薬科技有限公司Ｂｌｕｅｌｉｇｈｔ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．，Ｌｔｄ． | Method for preparing decoquinate solid dispersion |
| CN106137973A (en) * | 2016-08-10 | 2016-11-23 | 河南牧翔动物药业有限公司 | A kind of compound sulfonamide chloropyrazine soluble powder of sodium and preparation method thereof |
| CN106491538B (en) * | 2016-12-05 | 2019-01-08 | 郑州百瑞动物药业有限公司 | carbasalate calcium soluble powder and preparation method thereof |
| CN106491549B (en) * | 2016-12-14 | 2019-10-22 | 成都乾坤动物药业股份有限公司 | A kind of deccox dispersible tablet and its preparation method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129371A (en) * | 2007-08-26 | 2008-02-27 | 青岛康地恩实业有限公司 | Novel against-coccidia pharmaceutical formulation and technique of preparing the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9200339A (en) * | 1991-01-28 | 1992-08-01 | Hoechst Ag | PREPARED FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES, WHICH ARE APPROPRIATE AS THERAPEUTICS OR TO IMPROVE THE GROWTH AND USE OF FEED IN RUMINANTS |
| US6509040B1 (en) * | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| EP1942872A2 (en) * | 2005-11-04 | 2008-07-16 | Eastman Chemical Company | Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents |
-
2009
- 2009-07-10 CN CN2009100410221A patent/CN101606908B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129371A (en) * | 2007-08-26 | 2008-02-27 | 青岛康地恩实业有限公司 | Novel against-coccidia pharmaceutical formulation and technique of preparing the same |
Non-Patent Citations (7)
| Title |
|---|
| id=3477071& * |
| n=0》.2009,第1-3页. * |
| pri=& * |
| userid=52757354& * |
| 朱斌等.癸氧喹酯可溶性工艺研究.《http://blog1.poco.cn/myBlogDetail.htx& * |
| 朱斌等.癸氧喹酯可溶性工艺研究.《http://blog1.poco.cn/myBlogDetail.htx&id=3477071&userid=52757354&pri=&n=0》.2009,第1-3页. |
| 潘绮雯等.癸氧喹酯预混剂的含量测定方法的改进.《中国畜牧兽医学会动物药品学分会2008年学术年会论文集》.2008,第201-202页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101606908A (en) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101606908B (en) | Decoquinate soluble powder and preparation method thereof | |
| AU707949C (en) | Anthelmintic formulations | |
| CN101564376B (en) | Decoquinate solid dispersoid and preparation method thereof | |
| CN106137973A (en) | A kind of compound sulfonamide chloropyrazine soluble powder of sodium and preparation method thereof | |
| CN106176617A (en) | Amoxicillin soluble powder and preparation method thereof | |
| CN101129371A (en) | Novel against-coccidia pharmaceutical formulation and technique of preparing the same | |
| CN105454685A (en) | Application of tannin micro-capsule in preparation of pig feed additive | |
| CN104800167A (en) | Florfenicol soluble powder and preparation method thereof | |
| CN101843624B (en) | Method for preparing soluble powder for treating livestock/poultry coccidiosis | |
| CN108670956A (en) | A kind of amoxicillin soluble powder and preparation method thereof | |
| CN101623255B (en) | Artesunate nanoemulsion drug composition and preparation method thereof | |
| CN101632661A (en) | Compound amoxicillin slow release dry suspension composition and preparation method thereof | |
| CN110302386A (en) | Combination product comprising limonoid and sulfonylureas | |
| CN102755325A (en) | Cefoxitin sodium medicinal composition, powder injection and preparation method thereof | |
| CN102429918A (en) | Medicinal composition containing florfenicol and tea saponin and preparation method thereof | |
| CN101837118B (en) | Compound chicken colibacillosis resisting veterinary drug preparation | |
| CN106474055A (en) | A kind of novel composing prescription of solution of diclazuril and preparation method thereof | |
| CN106667898A (en) | Decoquinate preparation as well as preparation method and application thereof | |
| CN104771360A (en) | Artemether nanoemulsion pharmaceutical composition and preparation method thereof | |
| CN102727596B (en) | A kind of Chinese herbal granules for preventing chicken coccidiasis and preparation method thereof | |
| CN102008435B (en) | Avian decoquinate oral suspension and preparation method thereof | |
| CN101214223B (en) | Closantel or its sodium salt long-acting sustained-release injection and preparation thereof | |
| US20140275138A1 (en) | Method and products for treating diabetes | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN103536603A (en) | Wettable sulfamonomethoxine (sodium) powder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 510642 Guangdong city of Guangzhou province Tianhe District Wushan Southern China Nongda No. 9 near the school Applicant after: Guangzhou Experimental Veterinary Medicine Co., Ltd. of South China Agricultural University Address before: 510642 experimental veterinary drug factory, No. five, 483 mountain road, Guangdong, Guangzhou Applicant before: Experimental Veterinary Medicine Factory of South China Agricultural University |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: EXPERIMENTAL VETERINARY MEDICINE FACTORY OF SOUTH CHINA AGRICULTURAL UNIVERSITY TO: GUANGZHOU EXPERIMENTAL VETERINARY MEDICINE CO., LTD. OF SOUTH CHINA AGRICULTURAL UNIVERSITY |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510642 next to building 9 in Wushan South China Agricultural University, Tianhe District, Guangzhou, Guangdong Province Patentee after: Guangdong Huanong Gaoke biopharmaceutical Co.,Ltd. Address before: 510642 next to building 9 in Wushan South China Agricultural University, Tianhe District, Guangzhou, Guangdong Province Patentee before: GUANGZHOU SCAU EXPERIMENTAL VETERINARY MEDICINE Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |